Ya doesn’t make any sense. Even if chapter 7 or
Post# of 157784
(Total Views: 489)
Posted On: 01/30/2022 12:33:25 PM
Re: onestepahead #116818
Ya doesn’t make any sense. Even if chapter 7 or 11 was rly looming I would vote no. For the record I don’t think it is.
It makes absolutely no sense at this point. Any buyout would even further validate our results. It just solidifies what we think we already know of the drugs capabilities.
Even 10 billion would be a joke. Who knows at this point. We still don’t have the full picture on two major trials IMO. NASH and Cancer trials, but maybe someone else does. Even better whoever it was wanted the HIV data so they said hey here is a good law firm Sidney Austin us them to get your data….
It makes absolutely no sense at this point. Any buyout would even further validate our results. It just solidifies what we think we already know of the drugs capabilities.
Even 10 billion would be a joke. Who knows at this point. We still don’t have the full picture on two major trials IMO. NASH and Cancer trials, but maybe someone else does. Even better whoever it was wanted the HIV data so they said hey here is a good law firm Sidney Austin us them to get your data….
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36